Lupin Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne)".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has received approval from the U.S. FDA for its biosimilar product Armlupeg (Pegfilgrastim-unne), used in cancer treatment to prevent neutropenia (low white blood cell count) in patients undergoing chemotherapy. This biosimilar is a version of Amgen's blockbuster drug Neulasta, which generates billions in annual sales globally. The approval allows Lupin to launch the product in the U.S. market, opening access to a large and lucrative therapeutic segment. This strengthens Lupin's biosimilars portfolio and its presence in the U.S. specialty injectables market.
This is a positive development for Lupin shareholders as it adds a new revenue stream in the high-margin U.S. biosimilars space, potentially boosting future earnings and supporting stock sentiment in the near term.